New data from Phase 3 attain study of Janssen’s once-daily simeprevir compared to telaprevir in treatment-experienced adult patients with genotype 1 chronic hepatitis C
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE…
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...